Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals with and without diabetes.

OBJECTIVE To assess coronary heart disease (CHD) risk within levels of the joint distribution of non-HDL and LDL cholesterol among individuals with and without diabetes. RESEARCH DESIGN AND METHODS We used four publicly available data sets for this pooled post hoc analysis and confined the eligible subjects to white individuals aged > or = 30 years and free of CHD at baseline (12,660 men and 6,721 women). Diabetes status was defined as either "reported by physician-diagnosed and on medication" or having a fasting glucose level > or = 126 mg/dl at the baseline examination. The primary end point was CHD death. Within diabetes categories, risk was assessed based on lipid levels (in mg/dl): non-HDL <130 and LDL <100 (group 1); non-HDL <130 and LDL > or = 100 (group 2); non-HDL > or = 130 and LDL <100 (group 3); and non-HDL > or = 130 and LDL > or = 100 (group 4). Group 1 within those without diabetes was the overall reference group. RESULTS Of the subjects studied, approximately 6% of men and 4% of women were defined as having diabetes. A total of 773 CHD deaths occurred during the average 13 years of follow-up time. A Cox proportional hazard model was used to estimate the relative risk (RR) of CHD death. Those with diabetes had a 200% higher RR than those without diabetes. In a multivariate model, CHD risk in those with diabetes did not increase with increasing LDL, whereas it did increase with increasing non-HDL: RR (95% confidence interval) for group 1: 5.7 (2.0-16.8); group 2: 5.7 (1.6-20.7); group 3: 7.2 (2.6-19.8); and group 4: 7.1 (3.7-13.6). CONCLUSIONS Non-HDL is a stronger predictor of CHD death among those with diabetes than LDL and should be given more consideration in the clinical approach to risk reduction among diabetic patients.

[1]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[2]  M. Laakso,et al.  Dyslipidemia and Hyperglycemia Predict Coronary Heart Disease Events in Middle-Aged Patients With NIDDM , 1997, Diabetes.

[3]  Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes : a randomised placebo-controlled trial , 2022 .

[4]  Michael W Kattan,et al.  Judging new markers by their ability to improve predictive accuracy. , 2003, Journal of the National Cancer Institute.

[5]  Neil J Stone,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.

[6]  L. Wilkins Mortality after 10 1/2 years for hypertensive participants in the Multiple Risk Factor Intervention Trial. , 1990, Circulation.

[7]  P. Raskin,et al.  Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.

[8]  S. Haffner Management of Dyslipidemia in Adults With Diabetes , 1998, Diabetes Care.

[9]  S. Grundy,et al.  Management of Dyslipidemia in NIDDM , 1990, Diabetes Care.

[10]  C. Sempos,et al.  Divergence of the recent trends in coronary mortality for the four major race-sex groups in the United States. , 1988, American journal of public health.

[11]  Sarah Parish,et al.  MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.

[12]  S. Grundy Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. , 2002, Circulation.

[13]  W. Kannel,et al.  An investigation of coronary heart disease in families. The Framingham offspring study. , 1979, American journal of epidemiology.

[14]  W. Barthelmai,et al.  [Enzymatic determinations of glucose in the blood, cerebrospinal fluid and urine]. , 1962, Klinische Wochenschrift.

[15]  Nader Rifai,et al.  Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes. , 2004, Diabetes care.

[16]  Gary Longton,et al.  Limitations of the Odds Ratio in Gauging the Performance of a Diagnostic or Prognostic Marker , 2004 .

[17]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[18]  B. Brodie,et al.  A simplified method for the estimation of total cholesterol in serum and demonstration of its specificity. , 1952, The Journal of biological chemistry.

[19]  S. Grundy,et al.  Prevention Conference VI: Diabetes and Cardiovascular Disease: Executive Summary Conference Proceeding for Healthcare Professionals From a Special Writing Group of the American Heart Association , 2002, Circulation.

[20]  Peter W. F. Wilson The epidemiology of atherosclerotic disease , 2004 .

[21]  L. Wilkins Plasma Lipid Distributions in Selected North American Populations: The Lipid Research Clinics Program Prevalence Study THE LIPID RESEARCH CLINICS PROGRAM EPIDEMIOLOGY COMMITTEE , 1979, Circulation.

[22]  P. Demacker,et al.  Five methods for determining low-density lipoprotein cholesterol compared. , 1984, Clinical chemistry.

[23]  T. Dawber,et al.  The Framingham Study: The Epidemiology of Atherosclerotic Disease , 1980 .

[24]  S. Grundy,et al.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[25]  K. Jablonski,et al.  Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study. , 2003, Diabetes care.

[26]  W. Barthelmai,et al.  Enzymatische Bestimmungen der Glucose in Blut, Liquor und Harn , 1962, Klinische Wochenschrift.

[27]  G. Cooper Methods for determining the amount of glucose in blood. , 1973, CRC critical reviews in clinical laboratory sciences.

[28]  F. Harrell,et al.  Importance of clinical measures of ischemia in the prognosis of patients with documented coronary artery disease. , 1988, Journal of the American College of Cardiology.